Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Public ClinicalTrials.gov record NCT04459273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.
Study identification
- NCT ID
- NCT04459273
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 26 participants
Conditions and interventions
Conditions
- Bladder Carcinoma
- Cervical Carcinoma
- Cholangiocarcinoma
- Hematopoietic and Lymphoid Cell Neoplasm
- Hepatocellular Carcinoma
- Malignant Adrenal Gland Neoplasm
- Malignant Brain Neoplasm
- Malignant Pleural Neoplasm
- Malignant Skin Neoplasm
- Malignant Solid Neoplasm
- Malignant Testicular Neoplasm
- Malignant Thymus Neoplasm
- Neuroendocrine Neoplasm
- Thyroid Gland Carcinoma
- Urothelial Carcinoma
- Cancer of Unknown Primary Site
Interventions
- Computed Tomography Procedure
- Gallium Ga 68 FAPi-46 Drug
- Positron Emission Tomography Procedure
- 18F-FDG Radiation
Procedure · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2020
- Primary completion
- Jun 23, 2025
- Completion
- Jun 30, 2027
- Last update posted
- Feb 4, 2026
2020 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04459273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04459273 live on ClinicalTrials.gov.